张 昕, 衡 亮, 刘 军, 任引刚, 高砚丽, 张利华. CTRP6与冠状动脉慢血流的相关性及其可能机制[J]. 心脏杂志, 2015, 27(5): 596-599.
    引用本文: 张 昕, 衡 亮, 刘 军, 任引刚, 高砚丽, 张利华. CTRP6与冠状动脉慢血流的相关性及其可能机制[J]. 心脏杂志, 2015, 27(5): 596-599.
    CTRP6 is associated with coronary slow flow[J]. Chinese Heart Journal, 2015, 27(5): 596-599.
    Citation: CTRP6 is associated with coronary slow flow[J]. Chinese Heart Journal, 2015, 27(5): 596-599.

    CTRP6与冠状动脉慢血流的相关性及其可能机制

    CTRP6 is associated with coronary slow flow

    • 摘要: 目的 研究冠状动脉慢血流(CSF)现象与C1q肿瘤坏死因子相关蛋白6(CTRP6)的相关性,并初步探讨CTRP6影响CSF的潜在分子机制。方法 CSF组患者42例,正常血流组(对照组)45 例。根据校正的TIMI血流计帧法(cTFC)计算各支冠状动脉的TIMI帧数,采用生化法测定血清中CTRP6的含量。然后随机抽取6位CSF患者取外周血,分离培养其内皮祖细胞(EPCs),分别转染CTRP6的过表达载体pcDNA-CTRP6,3 d后用DdU法检测EPCs细胞增殖对EPCs进行计数,并检测转染前后转染组和对照组的培养基中CSF相关因子基质金属蛋白酶(MMP)-2和内皮素(ET)-1的分泌量变化。结果 CSF组的CTRP6水平显著低于对照组〔(1.2±0.5) vs.(2.7±1.0)〕 mg/L,P<0.01,Logistic回归分析表明血清CTRP6含量与CSF患者的cTFC呈负相关(β=-1.76),CTRP6是CSF的保护因素(OR=0.395);EPCs中过表达CTRP6引起EPCs数目显著上升(P<0.05),CSF负相关因子MMP-2水平被显著上调(P<0.01),正相关因子ET-1水平被显著下调(P<0.05)。结论 CSF组血清CTRP6水平低,血清CTRP6含量与CSF患者的cTFC呈负相关;CTRP6能够促进MMP-2和降低ET-1的分泌。

       

      Abstract: AIM To study the association between coronary slow flow (CSF) phenomenon and C1q tumor necrosis factor-related protein 6 (CTRP6), and to explore the potential molecular mechanism of CTRP6 impact on CSF. METHODS Each coronary artery blood flow TIMI frame was calculated using corrected TIMI frame count method (cTFC) in CSF group (n=42) and normal control group (n=45), and c1q tumor necrosis factor-related protein 6 in serum was determined using biochemical methods. Then, six CSF patients were randomly selected to phlebotomize peripheral blood, which was used to isolate and culture endothelial progenitor cells (EPCs). EPCs were transfected with pcDNA-CTRP6 overexpression vector. After 3 days, cell proliferation was detected using EdU method and the number of the cells was counted by an automated cell instrument. Finally, the secretion levels of CSF-related factors matrix metalloproteinase 2 (MMP-2) and endothelin-1 (ET-1) were examined and compared. RESULTS CTRP6 levels in CSF group were significantly lower than in control group [(1.2±0.5) vs.( 2.7±1.0) mg/L, P=0.002]. Logistic regression analysis showed that serum CTRP6 and cTFC content in CSF patients were negatively correlated (β=-1.76), and CTRP6 was a protective factor for CSF (OR=0.395). Moreover, CTRP6 overexpression resulted in a significant increase of EPC number (P<0.05). The secretion levels of MMP-2 were negatively correlated with CSF and were significantly upregulated (P<0.01). Levels of ET-1 positively correlated with CSF were significantly downregulated (P<0.05). CONCLUSION Serum CTRP6 level is lower and is negatively correlated with cTFC content in CSF patients. Serum CTRP6 is a protective factor for CSF and promotes MMP-2 and reduces ET-1 secretion.

       

    /

    返回文章
    返回